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Abstract: Men have been using herbal medicines for thousands of years. The 
advantages of this type of therapeutics include good availability, local cultural 
aspects, individual preferences, the increasing demand for natural and organic 
products, and the already validated synergistic effects of herbal medicines. 
However, ethically, the scope and limits of these drugs need to be established not 
only by ethnopharmacological evidences but also by scientific investigations, which 
confirm the therapeutic effects. With this study, we propose to discuss the possible 
advantages of using herbal medicines instead of purified compounds, the truth and 
myths about herbal medicines, drug discovery, and the implications for medical 
education and health care. 
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Introduction
 Chemical substances derived from animals, 
plants, and microbes have been used to treat diseases since 
the dawn of medicine (Koehn & Carter, 2005; Schmidt et 
al., 2008), while plant-derived products have dominated 
the human pharmacopoeia for thousands of years and 
have provided endless source of medicine (Schmidt et 
al., 2008). Although the medicinal use of willow (Salix 
sp.) dates back 6000 years (DerMarderosian & Beutler, 
2011), it was only in 1897 that the fi rst synthetic drug, 
aspirin, was created out of the salicylic acid extracted from 
willow barks. This discovery led to an era dominated by 
the pharmaceutical industry, characterized by the concept 
of mono-drug therapeutics to treat complex diseases and 
synthetic drug development by the advent of structure 
activity-guided organic synthesis and high throughput 
screening (HTS). Therefore, the use of natural products in 
drug discovery has been reduced. Synthetic pharmacology 
broke the connection between plants and human health, 
making modern medicine primarily dependent on 
medicines based on single synthetic or naturally-derived 
molecules, with a single mechanism of action (Raskin 
& Ripoll, 2004). Undoubtedly, this approach greatly 
improved medical care, human health, thus extending 
human life. Simultaneously, physicians started seeing the 
use of herbal medicines as an “alternative,” unqualifi ed, 
primitive, non-scientifi c health-care practice for those 
without access to “real” medical care. However, according 
to the World Health Organization (WHO), 70-95% of the 
world’s population rely on traditional medicine for their 
primary health care, and most of these practices include 
the use of plant extracts or their active components 
(Sardesai, 2002; Robinson & Zhang, 2011).
 Therefore, there is a huge gap between current 
“best medical practices” and the way people are actually 
treated all over the world. Sadly, the use of herbal 
medicines, aka phytotherapics, is hardly accepted by health 
care providers, mostly based on lack of knowledge. In this 
article we aimed to discuss the main aspects related to the 
use of herbal medicines, its acceptance by the medical 
community, potential advantages, and future directions.
Potential advantages of herbal medicines
Isolated compounds versus herbal extracts
 Usually, the natural product is extracted from 
the source, then concentrated, fractionated and purifi ed, 
yielding essentially a single biologically active compound 
(Koehn & Carter, 2005). It still is routine practice for 
scientists to investigate medicinal plants just to fi nd the 
single chemical substance responsible for the therapeutic 
effect (Williamson, 2001). Considering that the biological 
activity may be the result of the combination of several 
compounds, the isolation process may lead to its loss or 
reduction (Raskin & Ripoll, 2004). In fact, it is already well 
known that sometimes complex mixtures of compounds 
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in herbal medicines, aka phytocomplexes, have greater 
effects than isolated compounds (Gomez Castellanos et 
al., 2009). Information gathered from trials evaluating the 
action of whole plant extracts versus the action of purified 
preparation showed that, in many cases, the potency of the 
later declines as purification of the extract continues into 
more isolated fractions or single compounds (Cravotto et 
al., 2010). Thus, one of the advantages of herbal medicines 
is their complex composition. Their components have 
multiple activities that result in a greater total activity 
(Schmidt et al., 2008). Possible explanations include 
synergy, enhanced bioavailability, cumulative effects, or 
simply the addictive properties of the constituents, but 
further research is required (Williamson, 2001).
 Exointeractions (interactions with substances not 
present in the extract) and endointeractions (interactions 
between substances present within the extract) may 
have a profound effect on human health. Phytochemical 
interactions may explain the health effects of regional diets 
(like Mediterranean), undesirable side effects of drugs, 
and inconsistent performance of dietary supplements 
(Lila & Raskin, 2005). Endointeractions have already 
been demonstrated in tomatoes (lycopene), β-carotene, 
broccoli (sulforaphane), soy (isoflavones), St. John’s wort 
(hypericin, hyperforin), and cranberries (flavonoids), just 
to name a few (Lila & Raskin, 2005). A very good example 
can be found in the study by Capasso et al, who have shown 
that a standardized extract of Cannabis sativa is superior 
to its main compound, cannabidiol, in inhibiting both rat 
and human bladder contractility (Capasso et al., 2011).
 Isolation and purification of the active principles 
from an exceptionally complex matrix are the major 
bottlenecks affecting drug discovery from natural sources, 
and this reductionist approach may lead to inconclusive 
findings in clinical trials (Williamson, 2001; Raskin & 
Ripoll, 2004). Other reasons for not always isolating or 
fractioning a plant extract are the possible presence of 
unstable or unknown active constituents and the presence 
of a range of active compounds, rather than only one 
(Williamson, 2001).
The “herbal shotgun” approach: a multi-targeted 
approach
 Modern medicine advocates that an ideal 
therapeutic intervention should act on single, specific 
targets, like inhibiting an enzyme or binding to a receptor. 
Medical students are taught that the so called “silver 
bullet approach” (Williamson, 2001) is the more elegant, 
desirable, “right-way-to-do” pharmacotherapy. The 
alleged potential advantages of using a single molecule 
to treat diseases rely on the fact that it’s easier to study 
its pharmacokinetic and pharmacodynamic properties, 
mechanisms of action, interactions, and adverse effects. 
Also, the likelihood of an allergic reaction is potentially 
lower. The same authors described the use of herbal 
medicines as an “herbal shotgun” approach, due to the 
high number of chemical compounds present within the 
extracts (Williamson, 2001). We believe this is actually 
an advantage: although the use of a single molecule as 
treatment may fit the pathophysiology of some diseases, 
it may not for many others. Diseases with a multifactorial 
etiology, as well as those with a high incidence of resistance, 
or variable response to treatments, are usually treated 
using a combination of different drugs, aiming different 
targets. Examples include systemic arterial hypertension, 
atherosclerosis, type-2 diabetes mellitus, tuberculosis, 
cancer, infections by multi-resistant bacteria, heart failure, 
and septic shock (Williamson, 2001). Combination of 
chemotherapy has been the mainstay of cancer treatment 
for over 40 years. It is reasonable to assume that a mixture 
of compounds (phytochemicals or synthetic) would have 
greater bioactivity than a single compound because a 
mixture of bioactive compounds has the ability to affect 
multiple targets (Schmidt et al., 2008). Indeed, current 
guidelines for the treatment of several clinical conditions 
(e.g. septic shock) recommend the use of “bundles” of 
therapeutic interventions. These interventions have only 
been proven beneficial when used in association, and 
failed to show benefits when used alone (Nguyen et al., 
2007; Coba et al., 2011). Therefore, the combination of 
several therapeutic agents or drugs, aiming at different 
therapeutic targets, is actually already being advocated 
and practiced by modern medicine, and it is also the most 
claimed advantage of herbal medicines. In addition, it may 
be cheaper (Raskin & Ripoll, 2004).
Natural synergism
 Modern medicine has only recently learned how 
rapidly pathogens and cancer cells can develop resistance 
to single ingredient drugs, and that led to the administration 
of complex drug cocktails to circumvent or delay the 
resistance. Plants learned this strategy very early in their 
evolution in order to survive. By relying on combinations 
of pleiotropic, multi-targeted molecules, plants may 
have perfected interacting phytochemical complexes to 
accomplish many complementary tasks (Koehn & Carter, 
2005; Lila & Raskin, 2005). Natural products significantly 
differ from synthetic drugs by the frequency of different 
atoms, radicals and spatial configuration (Koehn & Carter, 
2005). They have less nitrogen, phosphorus, sulfur, 
halogens, and more overall molecular complexity, scaffold 
variety, stereochemical richness, ring system diversity, 
and carbohydrate constituents (Schmidt et al., 2008). 
Also, natural products have the capacity to modulate or 
inhibit protein-protein interactions. As a result, these 
molecules are effective modulators of cellular processes 
such as the immune response, signal transduction, mitosis 
and apoptosis (Koehn & Carter, 2005). Any natural 
Herbal medicines: old and new concepts
Fabio Carmona and Ana Maria Soares Pereira
Rev. Bras. Farmacogn. Braz. J. Pharmacogn. 23(2): Mar./Apr. 2013 381
product isolated from a plant is usually part of a “mini-
combinatorial library” of biochemically related analogues, 
precursors and catabolites that may have overlapping 
pharmacological activities (Raskin & Ripoll, 2004). While 
the functions of most secondary metabolites synthesized 
by plants are still obscure, a significant proportion of these 
metabolites play a role in defense and cell signaling both 
on cellular and organic levels. Thus, it is not surprising 
that mixtures of plant secondary metabolites could be 
more biologically active than individual components or a 
random combination of them (Lila & Raskin, 2005).
Synergism between natural products and synthetic 
compounds
 Resistance of microorganisms to multiple 
antibiotic drugs has also stimulated investigations 
on synergism between antibiotics and substances 
isolated from plants. Many studies have shown 
that the bioavailability of phenolic compounds like 
epigallocatechin gallate (EGCg), isolated from Camellia 
sinensis (Takahashi et al., 1995; Suresh et al., 1997), 
tellimagrandin I, present in Rosa canina (Shiota et 
al., 2000), and corilagin, isolated from Arctostaphylos 
uva-ursi (Shimizu et al., 2001), increase the inhibitory 
effect of commercially available antibiotics on the 
growth of microorganisms. Moreover, there are reports 
of potentiated antibiotic effects when associated with 
plant extracts like the ethanolic extract of Mangifera 
indica. These associations led to a 4-fold reduction 
on the MIC of tetracycline and erythromycin (Souto 
et al., 2011). Another example is the Tectona grandis 
methanolic extract. When associated with tetracycline, 
it has promoted a synergistic effect resulting in a 2-fold 
reduction on the MIC against Salmonella typhimurium 
strains, and a 4-fold reduction against Klebsiella 
pneumoniae (Purushotham et al., 2010). Synergism 
between phenolic compounds hydroxytyrosol, 
verbascoside, tyrosol and gallic acid isolated from Olive 
Mill Wastewater showed antimicrobial activity, at 100 
μg/mL, against Streptococcus pyogenes, Staphylococcus 
aureus, Escherichia coli, and Klebsiella pneumoniae 
(Tafesh et al., 2011). Pseudolaric acid isolated from 
plants used in traditional Chinese medicine showed 
synergistic effect with fluconazole against several 
Candida species (Yan et al., 2012). In vitro studies 
on the association of soybean-derived genistein and 
tamoxifen showed a synergistic effect on the inhibition 
and growth of some breast cancer lineages (Tanos et 
al., 2002), similarly to the synergistic effect observed 
between curcumin (from Curcuma longa) and cysplatin 
(Notarbartolo et al., 2005). Besides those, quercetin, 
EGCg, thearubigins, and catechin also exhibit 
synergistic effects with the main chemotherapeutic 
medicines available (HemaIswarya & Doble, 2006).
 The mechanisms of synergism among the 
compounds present in a single herbal extract are mainly 
related to two factors: the simultaneous solubility of a 
group of substances with different polarities, and the 
multiplicity of targets that these substances can act on, 
including enzymes, receptors, ion channels, transport 
proteins, antibodies, and many others (Wagner & Ulrich-
Merzenich, 2009)
Real and alleged limitations of herbal medicines
 Phytomedicine is not well accepted by the 
medical community and pharmaceutical industry because 
of a belief that it lacks safety and efficacy validation and 
regulations, as well as concerns on poor standardization 
and quality control, mistakes in nomenclature (Houghton, 
1998), difficulties in identifying active ingredients and 
determining their complex modes of action (Raskin & 
Ripoll, 2004). 
Lack of effect
 It’s a common belief that, in herbal medicines, 
the amount of supposedly active constituents is too low to 
have any relevant therapeutic effect at all. This assumption 
has led skeptics to dismiss these medicines as placebos 
(Williamson, 2001). This is not true. In a recent report of the 
American Association of Poison Control Center (AAPCC) 
on data from 1983-2009, in the United States, more than 
2 million plant ingestion exposures were reported, and 
only 18.5% of them could be categorized as nontoxic. 
The remaining cases were categorized as gastrointestinal 
irritants, skin irritants, anticholinergics, hallucinogens, 
depressants, and stimulants. Also, plant ingestion resulted 
in 45 deaths (0.002%) (Krenzelok & Mrvos, 2011). These 
findings clearly show that the ingestion of plants or herbal 
extracts can undoubtedly have significant biological 
effects.
Lack of specific regulations
 The indications and posology of plant-derived 
products vary widely across nations and continents, 
according to socioeconomic and cultural aspects, as 
well as to regulations. For example, ginger (Zingiber 
officinalis) can be used as medicine in Europe, as food 
supplement in the United States, and as tea in Brazil, 
where until recently, it was not considered medicine. Since 
2004, herbal medicines are FDA-regulated and defined as 
“complex extracts from a plant to be used for the treatment 
of disease.” They are clinically evaluated for safety and 
efficacy just as conventional drugs, but the process for 
botanical drugs can be expedited when there is history 
of safe human use (Raskin & Ripoll, 2004; Schmidt et 
al., 2008). Recently, Brazil has taken large steps towards 
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better regulations on botanical drugs, starting in 2006 with 
the “National Policies on Medicinal Plants and Herbal 
Medicines.” In the last few years, several regulations 
were published, addressing the use of botanical drugs (as 
infusions) without medical prescriptions (Anvisa, 2010a), 
the use herbal medicines with simplified registration 
(Anvisa, 2008), and other important issues. Brazil has 
also recently published an updated national pharmacopeia 
(Farmacopeia Brasileira, 2010) and a national herbal 
formulary (Anvisa, 2011). The new definitions brought by 
these regulations made nomenclature more clear (Chart 
1).
Chart 1. Definitions according to the Brazilian regulations.
Word Definition
Herbal medicine Any medicine obtained exclusively from vegetal 
raw material, with well-known efficacy, side 
effects and toxicity, as well as reproducibility 
and constancy of its quality. Its efficacy and 
safety are validated by etnopharmacological 
studies on traditional use, technical and scientific 
documentation, or in phase 3 clinical trials. 
Medicines that include in their compositions 
any isolated substance of any origin cannot be 
considered herbal medicines (Anvisa, 2004).
Herbal drug Any purified substance isolated from raw 
vegetal material with a particular chemical 
structure and pharmacological activity. They are 
used as an active principle in medicines. Isolated 
compounds that underwent any semisynthesis or 
chemical modification step cannot be considered 
herbal drugs (Anvisa, 2010b). 
Medicinal plant Any vegetal species, whether cultivated or not, 
used for therapeutic purposes (Anvisa, 2010b).
Marker Any compound of class of compounds (e.g. 
alkaloids, flavonoids, fatty acids) found in raw 
vegetal materials, that preferably are correlated 
with the therapeutic effect, which is used as a 
reference in quality control of the raw material 
and the herbal medicine (Anvisa, 2010b). 
Phytocomplex Any group of compounds originated from the 
plant’s primary and/or secondary metabolism 
that are responsible, in conjunction, for the 
biological effects of a medicinal plant or its 
derivatives (Anvisa, 2010b).
Complexity of drug discovery
 The use of natural products as a complex brings 
a challenge to their development as drugs. Indeed, 
important medicines such as ivermectin were developed 
and marketed in the past as complexes because it was not 
possible to purify the individual components at a sufficient 
scale (Koehn & Carter, 2005). The current method of 
drug discovery, HTS, is not easily adaptable to extracts 
produced from natural sources. This is mainly due to the 
high cost per sample, complexity of resupply, difficulty 
in isolation and characterization of actives compounds, 
lack of reproducibility, and interference from compounds 
in complex mixtures (Schmidt et al., 2008). In fact, the 
reductionist approach of modern pharmacology is not 
designed to study complex mixtures of substances (Lila 
& Raskin, 2005). Clearly, many technologies required for 
the successful discovery, development and production of 
herbal medicines are not yet in place, and efforts required 
for their emergence need to be substantial (Raskin & Ripoll, 
2004). Nevertheless, while new technology is not in place, 
ethnopharmacology still is more efficient to discover new 
drugs from plants.
Lack of evidence
 In a recent survey of roughly 1000 herbal 
medicines, only for 156 of them had clinical trials 
supporting specific pharmacological activities and 
therapeutic applications. Moreover, clinical trials 
actually failed to demonstrate activity for one-third 
of the studied medicines. In the same survey, the use 
of about 500 herbal medicines was supported only by 
in vitro and in vivo studies. In 200 of the 1000 herbal 
medicines, only phytochemical studies were found. 
Also, among the medicines currently available in the 
Western market, 12% of them did not have substantial 
studies published. Surprisingly, in this study, there was 
strong evidence that 1 in 200 medicines were toxic 
or allergenic, so their use should be discouraged or 
forbidden (Cravotto et al., 2010).
 In another recent study, only 35 studies (1.4%) 
from approximately 2500 citations on herbal medicines 
for arthritis met the criteria for inclusion in the review, 
and only six adequately met all six validity criteria and 
were at minimal risk of bias (Cameron et al., 2009). The 
main reason for excluding studies from this review were: 
a formal diagnosis was not established at baseline, the 
diagnostic criteria were inconsistent, heterogeneity of 
diagnostics, absence of control groups, randomization, 
or full study details, impossibility to identify the herbal 
components of the intervention, and inadequate statistical 
analysis (Cameron et al., 2009).
 Interestingly, there are many treatments with 
unknown efficacy. From around 3000 treatments currently 
used in modern medicine, it is estimated that a surprising 
proportion of 51% has unverified effectiveness, including 
many psychological, surgical, and medical interventions, 
such as cognitive behavioral therapy for depression 
in children, thermal balloon ablation for fibroids, and 
corticosteroids for wheezing in infants (Clinical Evidence, 
2011). There are some situations in which, although we 
know that a treatment was never proven to be effective, 
its wide use makes placebo-controlled studies on these 
interventions to be considered unethical (Als-Nielsen et 
al., 2004).
 It’s also said that many studies on herbal 
medicines, although well designed, are probably 
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underpowered and the observed lack of effect may be 
due to type II errors (Cameron et al., 2009). A type II 
statistical error refers to the situation where the study 
failed to reject the null hypothesis when it is actually 
false; in other words, it failed to detect an effect that 
actually exists. According to Descartes (Descartes, 
2011): “it is better to repudiate a dozen truths than 
to admit a single error, a false theory.” However, the 
amount of human and financial resources that are spent 
on these inconclusive studies could be better used. On 
the other hand, larger sample sizes may have the power 
to detect small “statistically significant” effects that are 
not necessarily translated into clinical benefit.
These findings show the need for future studies that comply 
with the current best scientific methods. Many efforts have 
been made in this direction, such as the Consolidated 
Standards of Reporting Trials (CONSORT) statement, 
which tries to help authors and editors to improve reporting 
of randomized controlled trials, including the herbal 
interventions ones (Gagnier et al., 2006). Some authors 
have suggested the creation of a database of clinical trials 
to improve the quality of study design. Clinicaltrials.gov 
is a good example of such initiative (National Institutes of 
Health, 2011).
 
Standardization
 Other contributing factors to the negative results 
of some trials are the functional and structural diversity 
of compounds in herbal medicines, variable content in 
different batches of plant materials, and inconsistent 
use of extraction methods and formulations (Raskin & 
Ripoll, 2004). Indeed, the complexity of plant extracts 
makes the development of an evidence-based herbal 
medicine a difficult task that requires a huge analytical 
effort and manufacturing skills to produce well-defined, 
standardized herbal preparations (Cravotto et al., 2010). 
There is also a need for the development of new methods 
for pharmacological studies and clinical trials evaluating 
the effects produced by complex mixtures of compounds 
(Lila & Raskin, 2005).
 Besides all that, there may be variation on the 
chemical composition of plants according to the climate, 
soil type, and interactions with the environment. We believe 
that urbanized, contaminated, or artificially fertilized 
areas are not adequate for production of medicinal plants. 
They should be cultivated in environments that mimic 
the wild as much as possible. This would provide an 
ecologically well-balanced medium with all the biotic and 
abiotic interactions that stimulate the metabolic routes. 
These routes produce the secondary metabolites that are 
responsible for the therapeutic effects. It is possible that, in 
the future, we will have specific areas for the production of 
certain medicinal plants, in the same fashion we have today 
with selected areas where different varieties of grapes are 
grown, resulting in wines with a particular flavor and 
bouquet. This scenario can contribute for a standardization 
that should start in the field throughout the post-harvest 
processes for the production of herbal medicines.
Education
 Ethical prescription of herbal medicines 
certainly depends on the application of methods of 
standardization that can assure a consistent chemical 
profile, the absence of contaminants and, consequently, 
desirable and reproducible therapeutic effects. It has 
become vital to educate health care professionals and 
show that there are some features which are unique to 
herbal medicines and which contribute both to efficacy 
and safety (Williamson, 2001; Raskin & Ripoll, 
2004). In recent surveys among American and German 
physicians and medical students, the self-evaluated 
knowledge about complementary and alternative 
medicine was poor (Abbott et al., 2011; Munstedt et 
al., 2011). Interestingly, both groups believed that it 
should be included in medical education; however, 
they believed that it demanded more investigation and 
should be taught criteriously (Munstedt et al., 2011). 
This would include choosing specific contents based 
on evidence, demographics and medical conditions, 
providing students with the skills that are necessary for 
future learning (Abbott et al., 2011; Munstedt et al., 
2011). This task can be more easily accomplished with 
the involvement of multidisciplinary teams, supported 
by medical schools and associations that have real 
interest in developing studies with strong scientific 
methodology, free of prejudice.
Conclusion
 Herbal medicines are widely used all over the 
world. However, there is still a huge gap between “best 
scientific evidence” and what people actually use to treat 
a disease. The lack of acceptance of herbal medicines 
by medical community is based both on false and true 
premises. It is important that the study of Herbal Medicine 
is offered to all health care professionals. Both research 
groups and the pharmaceutical industry should put their 
efforts on high-quality studies on herbal medicines, 
pursuing an “evidence-based herbal medicine,” making 
people’s health care better and safer. Maybe then we’ll see 
“health for all” as reality
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